146 related articles for article (PubMed ID: 8707164)
1. Pharmacological activities of heparin chains: should our past knowledge be revised?
Agnelli G
Haemostasis; 1996; 26 Suppl 2():2-9. PubMed ID: 8707164
[TBL] [Abstract][Full Text] [Related]
2. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
3. New data on the pharmacology of heparin and low molecular weight heparins.
Samama MM; Bara L; Gouin-Thibault I
Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of low molecular weight heparins.
Bara L; Samama M
Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
Padilla A; Gray E; Pepper DS; Barrowcliffe TW
Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
[TBL] [Abstract][Full Text] [Related]
6. [The Choay domain -- the structure responsible for the anticoagulant action of heparins].
Hemker HC; al Dieri R; Wagenvoord R; Béguin S
Bull Acad Natl Med; 2003; 187(1):59-66; discussion 66-7. PubMed ID: 14556454
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
Gray E; Padilla A; Barrowcliffe TW
Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
[TBL] [Abstract][Full Text] [Related]
8. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
9. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
[TBL] [Abstract][Full Text] [Related]
10. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
Ofosu FA; Smith LM; Anvari N; Blajchman MA
Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
[TBL] [Abstract][Full Text] [Related]
11. Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin).
Pèrez-Requejo JL; Lucena-Solano O; Pérez-García M; Santarelli MT
Thromb Res; 1997 Feb; 85(3):259-65. PubMed ID: 9058500
[TBL] [Abstract][Full Text] [Related]
12. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
13. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
Lin P; Sinha U; Betz A
Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
[TBL] [Abstract][Full Text] [Related]
14. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.
Verstraete M
Drugs; 1990 Oct; 40(4):498-530. PubMed ID: 1964634
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
Hirsh J
Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
[TBL] [Abstract][Full Text] [Related]
19. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of new synthetic heparin mimetics.
Hérault JP; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert JM
Thromb Haemost; 2002 Jun; 87(6):985-9. PubMed ID: 12083506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
